Marker Therapeutics, Inc. MRKR 深 沪
等待开盘 04-02 09:30:00 美东时间
1.31
+0.010
+0.77%
华盛通- 最 高1.35
- 今 开1.30
- 成交量 7.30万股
- 最 低 1.2901
- 昨 收 1.30
- 总市值 2184.18万
- 52周最高 4.07
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 0.8099
- 委 比 -97.09%
- 总股本 1667.31万
- 历史最高 99.00
- 量 比 0.66
- 振 幅 4.61%
- 历史最低 0.8099
- 每 手 1
- 风险率 0.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.47) by 81.68 percent. This is a 79.29 percent increase over losses of $(0.42) per share
03-19 05:35
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Marker Therapeutics reported promising clinical results for its MT-601 MAR-T cell therapy in relapsed non-Hodgkin lymphoma, with a 66% objective response rate and favorable safety profile. Research in pancreatic cancer showed encouraging outcomes, and the公司加强了生产能力并与Cellipont Bioservices合作。财务方面，截至2025年底，现金为17 million美元，R&D费用为11.8 million美元，净亏损为12.2 million美元。
03-18 21:31
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Marker Therapeutics, Inc. announced that its CEO, Dr. Juan Vera, will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. The presentation, titled "Next-Generation T Cell-Based Immunotherapies," will discuss the company's Multi-Antigen Recognizing (MAR) T cell platform. Interested investors can register and access the webcast through Marker's Investor Relations website. Dr. Vera and Marker’s...
02-18 13:00
Marker Therapeutics Sets Date for 2026 Annual Meeting
The latest announcement is out from Marker Therapeutics ( ($MRKR) ). On Februar...
02-10 05:33
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
Marker Therapeutics highlights advancements in Multi-Antigen Targeted T cell therapy for pancreatic cancer, which showed an 84.6% disease control rate in a Baylor study. Featured on *Good Morning America*, the therapy addresses a critical need in pancreatic cancer treatment. Marker plans to expand trials with enhanced antigen targeting and higher cell doses, supported by NIH and CPRIT funding.
01-26 12:00
Marker Therapeutics Highlights Nature Medicine Publication On Multi-Antigen T Cells In Pancreatic Cancer
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical studyStudy highlights correlation
01-05 20:17
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
A clinical study from Baylor College of Medicine demonstrates that Multi-Antigen Targeted T cells combined with front-line chemotherapy achieved an 84.6% disease control rate in pancreatic cancer patients, with a median overall survival of 14.1 months. The study, published in *Nature Medicine*, highlights the safety and potential of the therapy, correlating clinical benefits with T cell expansion and persistence. Marker Therapeutics, the company ...
01-05 12:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $10.
2025-12-08 22:44
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.47) by 74.74 percent. This is a 53.85 percent increase over losses of $(0.26) per share
2025-11-14 06:31
